Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Bottaro Website

Donald P. Bottaro, Ph.D.

Selected Publications

1)  Cecchi F, Lee YH, Peruzzi B, Lattouf J, Bottaro DP.
Bukowski RM, Figlin RA, Motzer RJ, eds.
The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma. In: Renal Cell Carcinoma: Molecular Targets and Clinical Applications.
Totowa NJ: The Humana Press; 2014. In Press. [Book Chapter]
2)  McNeil BK, Sorbellini M, Grubb RL, Apolo AB, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, Pinto P, Bottaro DP.
Preliminary Evaluation of Urinary Soluble Met as a Biomarker for Urothelial Carcinoma of the Bladder.
J Trans Med. 2014.
In Press. [Journal]
3)  Cecchi F, Lee YH, Bottaro DP.
Gelman E, Sawyers C, Rauscher F, eds.
HGF/Met Signaling in Cancer. In: Molecular Oncology: Causes of Cancer and Targets for Treatment.
Cambridge UK: Cambridge University Press; 2014. p. 204-217 [Book Chapter]
4)  Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J.
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue.
PLoS ONE. 9: e100586, 2014.
5)  Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM.
Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.
Nat Rev Urol. 11: 465-75, 2014.
6)  Zhang M, Luo Z, Liu H, Croce CM, Burke TR, Bottaro DP.
Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist.
Leukemia. 28: 948-51, 2014.
7)  Lee YH, Morrison BL, Bottaro DP.
Synergistic Signaling of Tumor Cell Invasiveness by Hepatocyte Growth Factor and Hypoxia.
J. Biol. Chem. [Epub ahead of print], 2014.
8)  Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
J. Clin. Oncol. 31: 181-6, 2013.
9)  Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS ONE. 8: e54014, 2013.
10)  Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N.
Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.
PLoS ONE. 7: e42717, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 8/19/2014.